Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572
- Citation:
- Neuro-oncology vol 11 (2) 232-232
- Meeting Instance:
- SNO 2009
- Year:
- 2009
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2773
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- D. Schiff J. Sarkaria P. Decker J. Buckner E. Galanis J. Dancey C. Giannini P. Brown M. Wiesenfeld K. Jaeckle
- Networks:
- Study
- NCCTG-N0572
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: